GastroMARK™ (ferumoxsil, oral suspension)

GastroMARK™ (ferumoxsil, oral suspension) , which is marketed and sold under the trade name Lumirem® (ferumoxsil, oral suspension) outside of the U.S, is our oral contrast agent used for delineating the bowel in magnetic resonance imaging, or MRI, and is approved and marketed in the U.S., Europe, and other countries through our licensees.

Important Safety Information for Gastromark™ (ferumoxsil, oral suspension)

Gastromark™ (ferumoxsil oral suspension) is contraindicated in patients with known or suspected intestinal perforation or obstruction or in patients with known allergy to its active or inactive ingredients. The most commonly noted adverse events were flatulence, diarrhea, abdominal pain, nausea and vomiting, which can be associated with aspiration. Precautions should be taken to avoid aspiration.